Joan Kucera

Aflibercept 8 mg in diabetic macular edema first to achieve sustained vision gains with up to 83% of patients extended to 16-24 weeks at two years

Berlin, June 29, 2023 – Bayer today announced the two-year (96 weeks) topline results of the pivotal clinical trial PHOTON investigating its novel aflibercept 8 mg with extended dosing regimens of up to 24 weeks in diabetic macular edema (DME) compared to the current standard of care EyleaTM (aflibercept 2 mg) with fixed intervals of

Joan Kucera September 15, 2023

Floods of nutrients from fertilisers and wastewater trash our rivers. Could offsetting help?

Credit: Shutterstock The rivers running through the hearts of Australia’s major cities and towns are often carrying heavy loads of nutrients and sediments. This is a problem. While nutrients like nitrogen and phosphorus are essential to life in small quantities, in large quantities they become destructive to river and ocean ecosystems. When rivers are pumped…

Joan Kucera April 21, 2023

Aflibercept 8 mg in diabetic macular edema first to achieve sustained vision gains with up to 83% of patients extended to 16-24 weeks at two years

Floods of nutrients from fertilisers and wastewater trash our rivers. Could offsetting help?

Do you want to boost your business today?

Learn how we helped 100 top brands gain success